Clinical research continues to evolve at an impressive pace. Digital technologies streamline data capture, biomarkers deepen biological insight, and innovative trial designs broaden access for diverse populations. These advances have unquestionably accelerated development and expanded participant reach. Still, across all this progress, one dimension consistently shapes outcomes yet remains underrepresented in planning, modeling, and oversight: patient behavior. Behavioral factors like motivation,
placebell
We are pleased to announce that Cognivia will participate in the Fortrea Innovation & Technology Summit in Boston on April 7, 2026. Our CEO, Dominique Demolle, will join the industry panel: “User Experience and Adoption Strategies: Why a Great Product Is Only One Factor in Success.” Speakers: This panel will explore how user experience, adoption
We are pleased to share that Cognivia will take part in the SAPA Annual Conference in Philadelphia on March 21, 2026. Our CEO, Dominique Demolle, will join the round‑table discussion: “From Data to ROI: How AI Impacts the Bottom Line of Drug Development.” Speakers: This session will explore how AI‑driven insights translate into measurable value
Cognivia is pleased to announce its participation in the OARSI World Congress 2026, taking place in Florida from April 23 to April 26, 2026. During the event, our team will present new findings on placebo response modelling using psychological characteristics in a remote osteoarthritis trial — an approach that strengthens signal detection and improves the
Patient retention or patient engagement have become a main operational challenge in today’s clinical trials. Despite major investments in decentralized models, engagement tools, and site‑facing technology, patient drop‑out still catches clinical operations teams by surprise. And when it does, the impact on timelines, data quality, and site oversight is immediate. A new upcoming webinar from Cognivia
At the recent 2025 Advanced Technologies & Treatments for Diabetes congress in Amsterdam, Cognivia presented two new scientific posters demonstrating the applicability and scientific robustness of its data-driven tools, Placebell and Compl-AI, in Type 1 Diabetes (T1D) clinical trials. These results mark a significant step forward in addressing two persistent challenges: data variability and patient drop-out, both of which can compromise statistical power